8-K: Court Denies FTC Bid to Block Surmodics-GTCR Merger

A U.S. District Court denied the FTC's request for a preliminary injunction, moving Surmodics' proposed acquisition by GTCR closer to completion.

Summary

• The U.S. District Court for the Northern District of Illinois denied the U.S. Federal Trade Commission's (FTC) request for a preliminary injunction.
• This injunction would have prevented Surmodics, Inc. and GTCR LLC from completing their proposed acquisition (the Merger).
• The Merger remains subject to a Temporary Restraining Order (TRO) preventing consummation before 5:00 p.m. CT on Monday, November 17, 2025.
• Consummation is also contingent on the absence of other legal restraints, no Company Material Adverse Effect, and other customary closing conditions.

Sentiment

Score: 8

Explanation: The denial of the preliminary injunction is a significant positive development for the merger, removing a major regulatory hurdle. While some conditions and a temporary restraining order remain, the primary legal challenge has been overcome, making the merger highly likely to proceed.

Positives

• The U.S. District Court denied the FTC's request for a preliminary injunction, removing a significant legal hurdle to the proposed acquisition.
• This ruling is considered a "significant step" towards completing the Merger.
• Management believes the Merger will position the Company to continue delivering compelling benefits for physicians, patients, and customers.

Negatives

• The Merger is still subject to a Temporary Restraining Order until November 17, 2025.
• Other closing conditions, including the absence of any other injunctions or a Company Material Adverse Effect, must still be met or waived.

Risks

• The Merger may not be consummated if other legal restraints or prohibitions arise.
• The Merger could be prevented if a Company Material Adverse Effect occurs.
• Other customary closing conditions set forth in the merger agreement may not be satisfied or waived.
• Inherent risks and uncertainties could cause actual results to differ materially from forward-looking statements.
• Factors identified under Risk Factors in the Annual Report on Form 10-K for the fiscal year ended September 30, 2024, and subsequent reports, could impact the Merger.

Future Outlook

The Company believes the Merger, once completed, will position it to continue delivering compelling benefits for physicians, patients, and customers. It is expected that the Company will be privately held after the Merger, which is also subject to expected financing.

Management Comments

• "The District Court's ruling is a significant step toward being able to complete the Merger, which we continue to believe will position the Company to continue to deliver compelling benefits for physicians, patients and customers going forward." Gary Maharaj, President and CEO of Surmodics, Inc.
• "I would like to extend a heartfelt thanks to our legal advisors for their hard work in helping Surmodics to defend this proposed transaction in court, and to our employees for their unwavering dedication to maintaining our excellent operating performance." Gary Maharaj.

Industry Context

This event highlights the increasing scrutiny by regulatory bodies like the FTC on mergers and acquisitions, particularly in the healthcare and medical device sectors, to prevent potential anti-competitive practices. The denial of the injunction suggests that the court did not find sufficient evidence of anti-competitive harm in this specific case, which could be seen as a positive signal for other companies navigating similar regulatory challenges in M&A.

Legal Proceedings

• The U.S. Federal Trade Commission (FTC) and certain state regulators requested a preliminary injunction to block the proposed acquisition of Surmodics by GTCR LLC.
• The United States District Court for the Northern District of Illinois denied this request.
• A Temporary Restraining Order is in place, preventing consummation of the Merger prior to 5:00 p.m. CT on Monday, November 17, 2025.

Stakeholder Impact

• Shareholders: The denial of the injunction likely increases the certainty of the merger closing, potentially leading to the realization of the acquisition price.
• Employees: Management thanked employees for their dedication, implying continued operations and potential integration into GTCR's affiliate post-merger.
• Physicians, Patients, and Customers: Management believes the merger will continue to deliver compelling benefits to these groups.

Next Steps

• Wait for the expiration of the Temporary Restraining Order at 5:00 p.m. CT on Monday, November 17, 2025.
• Satisfy or waive remaining closing conditions, including the absence of other injunctions or a Company Material Adverse Effect.
• Consummate the Merger.

Key Dates

Recommendation

The denial of the FTC's preliminary injunction request removes a significant regulatory barrier, making the acquisition by GTCR highly probable. For investors, this substantially de-risks the merger arbitrage play, suggesting a strong likelihood of realizing the acquisition price. The remaining conditions and temporary restraining order are standard procedural steps rather than fundamental obstacles.

Keywords

Surmodics, SRDX, GTCR, Merger, Acquisition, FTC, Preliminary Injunction, District Court, Medical Device, In Vitro Diagnostic, Healthcare